Market Research Logo

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

Summary

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Highlights



Key Questions Answered

  • The bipolar disorder market is heavily genericized and many key players have chosen to deprioritize the indication. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
  • The current late-stage bipolar disorder pipeline is sparse, with only two products in Phase III development. What impact will these drugs have on the market? How will they affect the treatment algorithm for bipolar disorder? Will these drugs fulfil any of the unmet needs for bipolar disorder?
  • The management of bipolar disorder patients is challenging and a large number of variables can impact treatment outcomes. How does the diagnosis and treatment of bipolar disorder differ amongst the 8MM? Which treatment options are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?
Key Findings
  • The main driver of growth in the bipolar disorder market will be the uptake of novel atypical antipsychotic products, such as Otsuka/Lundbeck’s Abilify Maintena and Allergan/Gedeon Richter/Mitsubishi Tanabe’s Vraylar. These agents are forecast to be the highest selling bipolar disorder products by 2024, accounting for 34.9% of the bipolar disorder market in the 8MM.
  • There are very few products approved for the treatment of major depressive episodes, despite the fact that patients most commonly experience this episode type. This unmet need is not expected to be addressed during the forecast period due to the sparsity of the late-stage pipeline.
  • The biggest barrier for growth in the bipolar disorder market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
  • Considerable opportunity remains for products with superior safety profiles compared to the currently available drugs. KOLs noted that EPS and metabolic changes were significant concerns related to the antipsychotic drugs.
Scope
  • Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized bipolar disorder market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the bipolar disorder therapeutics market.
  • Pipeline analysis: focus on two late-stage pipeline bipolar disorder drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of off-label treatments.
  • Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buyThe report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global bipolar disorder therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bipolar disorder therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global bipolar disorder therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.5 Epidemiological Forecast of Bipolar Disorder (2014-2024)
4.5.1 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder
4.5.2 12-Month Total Prevalent Cases of Bipolar I
4.5.3 12-Month Total Prevalent Cases of Bipolar II
4.5.4 12-Month Total Prevalent Cases of Cyclothymic Disorder
4.5.5 Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder
4.5.6 Age-Specific 12-Month Total Prevalent Cases of Bipolar I
4.5.7 Age-Specific 12-Month Total Prevalent Cases of Bipolar II
4.5.8 Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
4.5.9 Sex-Specific 12-Month Total Prevalent Cases of Bipolar I
4.5.10 Sex-Specific 12-Month Total Prevalent Cases of Bipolar II
4.5.11 Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
4.5.12 Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis Overview
5.1.1 Clinical Evaluation
5.1.2 Screening Tools
5.2 Treatment Overview
5.2.1 Treatment Initiation and Maintenance Therapy
5.2.2 Manic or Mixed Episodes
5.2.3 Acute Agitation
5.2.4 Hypomanic Episodes
5.2.5 Major Depressive Episodes
5.2.6 Rapid Cycling
5.2.7 Cyclothymia
5.2.8 Other Treatment Factors
5.3 Treatment Guidelines and Leading Prescribed Drugs
5.4 US
5.5 5EU
5.6 Japan
5.7 Canada
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Major Brands
6.2.1 Lithium
6.2.2 Anticonvulsants
6.2.3 Typical Antipsychotics
6.2.4 Atypical Antipsychotics
6.2.5 Antidepressants
6.3 Other Therapeutic Classes
7 Unmet Need and Opportunity
7.1 Overview
7.2 Effective Treatment Options for Bipolar Depression
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Mood Stabilizers with Improved Safety Profiles
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Education for Physicians in Order to Improve Diagnosis Rates
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Novel Drugs Developed Specifically for Bipolar Disorder
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.1.1 Clinical Trials by Class of Therapy
8.2 Promising Drugs in Clinical Development
8.2.1 Abilify Maintena
8.2.2 ITI-007
8.3 Off-label Pipeline and Recently Approved Therapies
8.4 Promising Drugs in Early-Stage Development
8.5 Other Drugs in Development
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Otsuka
9.3.2 AstraZeneca
9.3.3 Eli Lilly
9.3.4 Allergan
9.3.5 Dainippon Sumitomo
9.3.6 Janssen
9.3.7 Lundbeck
9.3.8 Meiji Seika
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 United States
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 Canada
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Bipolar Disorder Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Launch and Patent Expiry Dates
11.4.4 General Pricing Assumptions
11.4.5 Individual Drug Assumptions
11.4.6 Generic Erosion
11.5 Primary Research - KOLs Interviewed for this Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Therapy Area Director
11.7.3 Epidemiologist
11.7.4 Global Director of Therapy Research and Analysis
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM
Table 2: DSM-V Bipolar Disorder Specifiers
Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder
Table 4: Risk Factors and Comorbidities for Bipolar Disorder
Table 5: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder I
Table 6: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder I
Table 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder II
Table 8: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder II
Table 9: 8MM, Sources Used to Forecast 12-Month Total Prevalent Cases of Cyclothymic Disorder
Table 10: 8MM, Sources Used to Forecast Lifetime Total Prevalent Cases of Cyclothymic Disorder
Table 11: 8MM, 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014
Table 12: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, 2014-2024
Table 13: 8MM, 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages ≥13 Years, 2014-2024
Table 14: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, 2014-2024
Table 15: 8MM, Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014
Table 16: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, N (Row %), 2014
Table 17: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages ≥13 Years, N (Row %), 2014
Table 18: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, N (Row %), 2014
Table 19: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages ≥13 Years, N (Row %), 2014
Table 20: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages ≥13 Years, N (Row %), 2014
Table 21: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages ≥13 Years, N (Row %), 2014
Table 22: Screening Tools Used for Bipolar Disorder
Table 23: Treatment Guidelines for Bipolar Disorder
Table 24: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014
Table 25: Country Profile - US
Table 26: Country Profile - 5EU
Table 27: Country Profile - Japan
Table 28: Country Profile - Canada
Table 29: Leading Treatments for Bipolar Disorder, 2015
Table 30: Product Profile - Lithium
Table 31: Lithium SWOT Analysis, 2015
Table 32: Global Sales Forecasts ($m) for Lithium, 2014-2024
Table 33: Product Profile - Carbamazepine
Table 34: Efficacy Results for Equetro in Bipolar Mania Trials
Table 35: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Equetro
Table 36: Carbamazepine SWOT Analysis, 2015
Table 37: Global Sales Forecasts ($m) for Carbamazepine, 2014-2024
Table 38: Product Profile - Lamotrigine
Table 39: Adverse Events at ≥5% Incidence in Bipolar Maintenance Trials of Lamictal
Table 40: Lamotrigine SWOT Analysis, 2015
Table 41: Global Sales Forecasts ($m) for Lamotrigine, 2014-2024
Table 42: Product Profile - Valproate
Table 43: Efficacy Results for Depakote in Bipolar Mania Trials
Table 44: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Depakote
Table 45: Valproate SWOT Analysis, 2015
Table 46: Global Sales Forecasts ($m) for Valproate, 2014-2024
Table 47: Typical Antipsychotics by Chemical Class
Table 48: Typical antipsychotics SWOT Analysis, 2015
Table 49: Global Sales Forecasts ($m) for the Typical Antipsychotics, 2014-2024
Table 50: Product Profile - Adasuve
Table 51: Efficacy Results for Adasuve in Agitation Trial of Bipolar I Disorder Patients
Table 52: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve
Table 53: Adasuve SWOT Analysis, 2015
Table 54: Global Sales Forecasts ($m) for Adasuve, 2014-2024
Table 55: Product Profile - Abilify
Table 56: Efficacy Results for Abilify in Bipolar Mania Trials
Table 57: Efficacy Results for Abilify in Agitation Trials
Table 58: Adverse Events at ≥2% Incidence in Bipolar I Disorder and Schizophrenia Trials of Abilify
Table 59: Abilify SWOT Analysis, 2015
Table 60: Global Sales Forecasts ($m) for Abilify, 2014-2024
Table 61: Product Profile - Geodon
Table 62: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Geodon
Table 63: Geodon SWOT Analysis, 2015
Table 64: Global Sales Forecasts ($m) for Geodon, 2014-2024
Table 65: Product Profile - Latuda
Table 66: Efficacy Results for Latuda in Bipolar Depression Trials
Table 67: Adverse Events at ≥2% Incidence in Bipolar Depression Trials of Latuda
Table 68: Latuda SWOT Analysis, 2015
Table 69: Global Sales Forecasts ($m) for Latuda, 2014-2024
Table 70: Product Profile - Risperdal
Table 71: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes
Table 72: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Risperdal
Table 73: Adverse Events at ≥2% Incidence in Bipolar Maintenance Trials of Risperdal Consta
Table 74: Risperdal SWOT Analysis, 2015
Table 75: Global Sales Forecasts ($m) for Risperdal, 2014-2024
Table 76: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024
Table 77: Product Profile - Saphris
Table 78: Efficacy Results for Saphris in Bipolar Mania Studies
Table 79: Adverse Events at ≥2% Incidence in Bipolar I Disorder Trials of Saphris
Table 80: Saphris SWOT Analysis, 2015
Table 81: Global Sales Forecasts ($m) for Saphris, 2014-2024
Table 82: Product Profile - Seroquel
Table 83: Efficacy Results for Seroquel in Bipolar Mania Studies
Table 84: Efficacy Results for Seroquel in Bipolar Depression Trials
Table 85: Efficacy Results for Seroquel XR in Bipolar Disorder Trials
Table 86: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel
Table 87: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel XR
Table 88: Seroquel SWOT Analysis, 2015
Table 89: Global Sales Forecasts ($m) for Seroquel, 2014-2024
Table 90: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024
Table 91: Product Profile - Symbyax
Table 92: Efficacy Results for Symbyax in Bipolar Depression Trials
Table 93: Adverse Events at ≥2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax
Table 94: Symbyax SWOT Analysis, 2015
Table 95: Global Sales Forecasts ($m) for Symbyax, 2014-2024
Table 96: Product Profile - Vraylar
Table 97: Vraylar SWOT Analysis, 2015
Table 98: Global Sales Forecast ($) for Vraylar, 2014-2024
Table 99: Product Profile - Zyprexa
Table 100: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Zyprexa
Table 101: Adverse Events at ≥2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania
Table 102: Zyprexa SWOT Analysis, 2015
Table 103: Global Sales Forecasts ($m) for Zyprexa, 2014-2024
Table 104: Product Information for the Most Commonly Prescribed “Other Antipsychotics”
Table 105: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder
Table 106: Antidepressants SWOT Analysis, 2015
Table 107: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024
Table 108: Summary of Minor Therapeutic Classes, 2015
Table 109: Unmet Need and Opportunity in Bipolar Disorder
Table 110: Product Profile - Abilify Maintena
Table 111: Adverse Events at ≥2% Incidence in a Schizophrenia Trial of Abilify Maintena
Table 112: Abilify Maintena SWOT Analysis, 2015
Table 113: Global Sales Forecast ($) for Abilify Maintena, 2014-2024
Table 114: Product Profile - ITI-007
Table 115: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial
Table 116: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007
Table 117: ITI-007 SWOT Analysis, 2015
Table 118: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs
Table 119: Drugs in Development, 2015
Table 120: Key Companies in the Bipolar Disorder Market in the 8MM, 2015
Table 121: Otsuka’s Bipolar Disorder Portfolio Assessment, 2015
Table 122: AstraZeneca’s Bipolar Disorder Portfolio Assessment, 2015
Table 123: Eli Lilly’s Bipolar Disorder Portfolio Assessment, 2015
Table 124: Allergan’s Bipolar Disorder Portfolio Assessment, 2015
Table 125: Dainippon Sumitomo’s Bipolar Disorder Portfolio Assessment, 2015
Table 126: Janssen Bipolar Disorder Portfolio Assessment, 2015
Table 127: Lundbeck Bipolar Disorder Portfolio Assessment, 2015
Table 128: Meiji Seika Bipolar Disorder Portfolio Assessment, 2015
Table 129: Global Sales Forecast ($m) for Bipolar Disorder, 2014-2024
Table 130: Bipolar Disorder Market - Drivers and Barriers, 2014-2024
Table 131: Sales Forecast ($m) for Bipolar Disorder in the US, 2014-2024
Table 132: Key Events Impacting Sales for Bipolar Disorder in the US, 2014-2024
Table 133: Bipolar Disorder Market in the US - Drivers and Barriers, 2014-2024
Table 134: Sales Forecasts ($m) for Bipolar Disorder in the 5EU, 2014-2024
Table 135: Key Events Impacting Sales for Bipolar Disorder in the 5EU, 2014-2024
Table 136: Bipolar Disorder Market in the 5EU - Drivers and Barriers, 2014-2024
Table 137: Sales Forecasts ($m) for Bipolar Disorder in Japan, 2014-2024
Table 138: Key Events Impacting Sales for Bipolar Disorder in Japan, 2014-2024
Table 139: Bipolar Disorder Market in Japan - Drivers and Barriers, 2014-2024
Table 140: Sales Forecasts ($m) for Bipolar Disorder in Canada, 2014-2024
Table 141: Key Events Impacting Sales for Bipolar Disorder in Canada, 2014-2024
Table 142: Bipolar Disorder Market in Canada - Drivers and Barriers, 2014-2024
Table 143: Key Launch Dates
Table 144: Key Patent Expiries
Table 145: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: The Etiology and Pathophysiology of Bipolar Disorders
Figure 2: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, 2014-2024
Figure 3: 8MM, Bipolar II 12-Month Total Prevalent Cases, Both Sexes, Ages ≥13 Years, 2014-2024
Figure 4: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, 2014-2024
Figure 5: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, 2014
Figure 6: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, 2014
Figure 7: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, 2014
Figure 8: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages ≥13 Years, 2014
Figure 9: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages ≥13 Years, 2014
Figure 10: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages ≥13 Years, 2014
Figure 11: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Men, Ages ≥13 Years, 2014
Figure 12: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Women, Ages ≥13 Years, 2014
Figure 13: The Effects of Lithium on Neurotransmission
Figure 14: The Effects of Lithium on Second Messenger Pathways
Figure 15: Bipolar Disorder Therapeutics - Class of Therapy, 2016
Figure 16: Bipolar Disorder - Phase II-III Pipeline, 2015
Figure 17: Clinical and Commercial Positioning of Abilify Maintena
Figure 18: Clinical and Commercial Positioning of ITI-007
Figure 19: Global Sales of Products for Bipolar Disorder by Company, 2014-2024
Figure 20: Company Portfolio Gap Analysis in Bipolar Disorder, 2014-2024
Figure 21: Otsuka SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 22: AstraZeneca SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 23: Eli Lilly SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 24: Allergan SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 25: Dainippon Sumitomo SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 26: Janssen SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 27: Lundbeck SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 28: Meiji Seika SWOT Analysis in Bipolar Disorder, 2014-2024
Figure 29: Global Sales for Bipolar Disorder by Region, 2014-2024
Figure 30: Global Sales for Bipolar Disorder by Drug Class, 2014-2024
Figure 31: Sales for Bipolar Disorder in the US by Drug Class, 2014-2024
Figure 32: Sales for Bipolar Disorder in the 5EU by Drug Class, 2014-2024
Figure 33: Sales for Bipolar Disorder in Japan by Drug Class, 2014-2024
Figure 34: Sales for Bipolar Disorder in Canada by Drug Class, 2014-2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report